STOCK TITAN

Indaptus Therapeutics, Inc. - INDP STOCK NEWS

Welcome to our dedicated news page for Indaptus Therapeutics (Ticker: INDP), a resource for investors and traders seeking the latest updates and insights on Indaptus Therapeutics .

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Indaptus Therapeutics 's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Indaptus Therapeutics 's position in the market.

-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
18.8%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.98%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.99%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.88%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.77%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.73%
Tags
conferences
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.67%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.55%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.25%
Tags
management
Indaptus Therapeutics, Inc.

Nasdaq:INDP

INDP Rankings

INDP Stock Data

17.30M
5.90M
30.87%
7.05%
1.17%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
NEW YORK

About INDP

the indaptus goal is simple: to cure disease with the ability to harness both the body’s innate and adaptive immune responses, we believe we are uniquely positioned to revolutionize the treatment of cancer and certain infectious diseases. building on the observation that tumor regression can occur in the setting of bacterial infection, we have developed a proprietary platform that exploits bacteria’s natural ability to activate both innate and adaptive cellular immune pathways. leveraging our novel insights into the levels and ratios of activating signals needed to safely elicit a broad immune response, we are creating and advancing a pipeline of proprietary, attenuated and killed non-pathogenic gram-negative bacterial candidates designed to be widely accessible, with broad anti-tumor and anti-viral activity.